10/18/2024

Janusmed sex and gender

Janusmed sex and gender – alfacalcidol

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
B B
B B

Alfacalcidol

Alfacalcidol

Class : B

Show all info

Print

Contact us

  1. Dollery C Sir, editor. Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone; 1999

  2. Leo Pharma. Clinical Study Report Efficacy of po and iv Alfacalcidol in the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Renal Failure . Leo Pharma [www]. [updated 2007-09-27, cited 2019-07-25].

  3. Avenell A, Mak JC, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev. 2014;14(4):CD000227.

  4. Dukas L, Bischoff HA, Lindpaintner LS, Schacht E, Birkner-Binder D, Damm TN et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc. 2004;52(2):230-6.

  5. Richy F, Ethgen O, Bruyere O, Reginster JY. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int. 2004;15(4):301-10.

  6. Hayashi Y, Fujita T, Inoue T . Decrease of vertebral fracture in osteoporotics by administration of 1α-hydroxy-vitamin D3. Journal of Bone and Mineral Metabolism. 1992;10(2):50-54.

  7. Ikeda T, Maruyama K, Kaji H, Akagi M. Effects of alendronate or alfacalcidol on bone metabolic indices and bone mineral density in patients with ophthalmologic disease treated with glucocorticoid. Mod Rheumatol. 2014;24(4):671-6.

  8. Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A et al. Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. Hepat Mon. 2013;13(12):e14872.

  9. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-08-19.]

  1. Dollery C Sir, editor. Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone; 1999
  2. Leo Pharma. Clinical Study Report Efficacy of po and iv Alfacalcidol in the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Renal Failure . Leo Pharma [www]. [updated 2007-09-27, cited 2019-07-25].
  3. Avenell A, Mak JC, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev. 2014;14(4):CD000227.
  4. Dukas L, Bischoff HA, Lindpaintner LS, Schacht E, Birkner-Binder D, Damm TN et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc. 2004;52(2):230-6.
  5. Richy F, Ethgen O, Bruyere O, Reginster JY. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int. 2004;15(4):301-10.
  6. Hayashi Y, Fujita T, Inoue T . Decrease of vertebral fracture in osteoporotics by administration of 1α-hydroxy-vitamin D3. Journal of Bone and Mineral Metabolism. 1992;10(2):50-54.
  7. Ikeda T, Maruyama K, Kaji H, Akagi M. Effects of alendronate or alfacalcidol on bone metabolic indices and bone mineral density in patients with ophthalmologic disease treated with glucocorticoid. Mod Rheumatol. 2014;24(4):671-6.
  8. Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A et al. Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. Hepat Mon. 2013;13(12):e14872.
  9. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-08-19.]